Effects of Obstructive Sleep Apnea and Obesity on Morphine Pharmacokinetics in Children.
Age Factors
Analgesics, Opioid
/ administration & dosage
Biomarkers
/ blood
Biotransformation
Child
Child, Preschool
Drug Dosage Calculations
Female
Humans
Leptin
/ blood
Male
Models, Biological
Morphine
/ administration & dosage
Pediatric Obesity
/ blood
Sleep Apnea, Obstructive
/ blood
Surgical Procedures, Operative
Journal
Anesthesia and analgesia
ISSN: 1526-7598
Titre abrégé: Anesth Analg
Pays: United States
ID NLM: 1310650
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
pubmed:
7
11
2019
medline:
18
11
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
Obesity increases susceptibility to chronic pain, increases metabolism, and is associated with obstructive sleep apnea syndrome (OSAS), all which can complicate perioperative pain management of patients. In addition, obesity and OSAS can cause elevation of the adipose-derived hormone leptin, which increases metabolism. We hypothesized that obesity along with sleep apnea and leptin independently enhance morphine pharmacokinetics. Children 5-12 years of age who were presenting for surgery were administered a morphine dose of 0.05 mg/kg. Blood was collected at baseline and at subsequent preset times for pharmacokinetic analysis of morphine and its metabolites. Three groups were studied: a nonobese group with severe OSAS, an obese group with severe OSAS, and a control group. Thirty-four patients consisting of controls (n = 16), nonobese/OSAS (n = 8), and obese/OSAS (n = 10) underwent analysis. The obese/OSAS group had a higher dose-adjusted mean maximum morphine concentration (CMAX) over 540 minutes compared to the controls (P < .001) and those with only OSAS (P = .014). The obese/OSAS group also had lower volume of distribution (Vd) when compared to OSAS-only patients (P = .007). In addition, those in the obese/OSAS group had a higher morphine 3-glucuronide (M3G) maximum concentration (P = .012) and a higher ratio of M3G to morphine than did the control group (P = .011). Time to maximum morphine 6-glucuronide (M6G) concentration was significantly lower in both nonobese/OSAS and obese/OSAS groups than in the control group (P < .005). C-reactive protein (CRP), interleukin (IL)-10, and leptin were all higher in the obese/OSAS group than in controls (P = .004, 0.026, and <0.001, respectively), and compared to OSAS-only patients, CRP (P = .013) and leptin (P = .002) levels were higher in the obese/OSAS group. The combination of obesity and OSAS was associated with an increase in morphine metabolism compared with that in normal-weight controls. Our previous study in mice demonstrated that obesity from leptin deficiency decreased morphine metabolism, but that metabolism normalized after leptin replacement. Leptin may be a cause of the increased morphine metabolism observed in obese patients.
Sections du résumé
BACKGROUND
Obesity increases susceptibility to chronic pain, increases metabolism, and is associated with obstructive sleep apnea syndrome (OSAS), all which can complicate perioperative pain management of patients. In addition, obesity and OSAS can cause elevation of the adipose-derived hormone leptin, which increases metabolism. We hypothesized that obesity along with sleep apnea and leptin independently enhance morphine pharmacokinetics.
METHODS
Children 5-12 years of age who were presenting for surgery were administered a morphine dose of 0.05 mg/kg. Blood was collected at baseline and at subsequent preset times for pharmacokinetic analysis of morphine and its metabolites. Three groups were studied: a nonobese group with severe OSAS, an obese group with severe OSAS, and a control group.
RESULTS
Thirty-four patients consisting of controls (n = 16), nonobese/OSAS (n = 8), and obese/OSAS (n = 10) underwent analysis. The obese/OSAS group had a higher dose-adjusted mean maximum morphine concentration (CMAX) over 540 minutes compared to the controls (P < .001) and those with only OSAS (P = .014). The obese/OSAS group also had lower volume of distribution (Vd) when compared to OSAS-only patients (P = .007). In addition, those in the obese/OSAS group had a higher morphine 3-glucuronide (M3G) maximum concentration (P = .012) and a higher ratio of M3G to morphine than did the control group (P = .011). Time to maximum morphine 6-glucuronide (M6G) concentration was significantly lower in both nonobese/OSAS and obese/OSAS groups than in the control group (P < .005). C-reactive protein (CRP), interleukin (IL)-10, and leptin were all higher in the obese/OSAS group than in controls (P = .004, 0.026, and <0.001, respectively), and compared to OSAS-only patients, CRP (P = .013) and leptin (P = .002) levels were higher in the obese/OSAS group.
CONCLUSIONS
The combination of obesity and OSAS was associated with an increase in morphine metabolism compared with that in normal-weight controls. Our previous study in mice demonstrated that obesity from leptin deficiency decreased morphine metabolism, but that metabolism normalized after leptin replacement. Leptin may be a cause of the increased morphine metabolism observed in obese patients.
Identifiants
pubmed: 31688081
doi: 10.1213/ANE.0000000000004509
pmc: PMC7301293
mid: NIHMS1597863
pii: 00000539-202009000-00030
doi:
Substances chimiques
Analgesics, Opioid
0
Biomarkers
0
LEP protein, human
0
Leptin
0
Morphine
76I7G6D29C
Types de publication
Comparative Study
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
876-884Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL114800
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : ErratumIn
Références
Chem Res Toxicol. 2006 May;19(5):701-9
pubmed: 16696573
Proc Am Thorac Soc. 2008 Feb 15;5(2):274-82
pubmed: 18250221
Sleep. 2007 Apr;30(4):443-9
pubmed: 17520788
Anesth Analg. 2006 Nov;103(5):1115-21
pubmed: 17056942
Clin Pharmacokinet. 2012 May 1;51(5):277-304
pubmed: 22448619
Anesthesiology. 1992 Jan;76(1):85-90
pubmed: 1729941
Anesth Analg. 2007 Jan;104(1):147-53
pubmed: 17179260
Br J Clin Pharmacol. 2002 Dec;54(6):592-603
pubmed: 12492606
Methods Mol Biol. 2012;929:377-89
pubmed: 23007438
Paediatr Anaesth. 2010 Dec;20(12):1078-83
pubmed: 21199116
Paediatr Anaesth. 2012 Dec;22(12):1171-8
pubmed: 22776351
Sci Rep. 2017 Feb 17;7:42658
pubmed: 28211545
Semin Nephrol. 2013 Jan;33(1):54-65
pubmed: 23374894
Clin Pharmacol Ther. 1978 Jul;24(1):52-9
pubmed: 657720
Arch Otolaryngol Head Neck Surg. 2006 May;132(5):476-80
pubmed: 16702561
Clin Pharmacokinet. 2014 Oct;53(10):919-30
pubmed: 25141973
Chest. 2000 Sep;118(3):580-6
pubmed: 10988175
J Biol Chem. 2012 Nov 23;287(48):40441-7
pubmed: 23024365
Clin Pharmacokinet. 2017 Dec;56(12):1577-1587
pubmed: 28510797
Am J Respir Crit Care Med. 1999 May;159(5 Pt 1):1527-32
pubmed: 10228121
Anesth Analg. 2010 Apr 1;110(4):1093-101
pubmed: 20142343
Am J Respir Crit Care Med. 2008 May 15;177(10):1142-9
pubmed: 18276939
Anesth Analg. 2016 Dec;123(6):1611-1617
pubmed: 27782940
Drug Metab Dispos. 2002 Nov;30(11):1257-65
pubmed: 12386133
Sleep Breath. 2015 May;19(2):561-8
pubmed: 25108706
Anesth Analg. 2009 Jul;109(1):60-75
pubmed: 19535696
Laryngoscope. 2013 Sep;123(9):2281-4
pubmed: 23821577
Can J Anaesth. 2012 Oct;59(10):974-96
pubmed: 22833138
JAMA. 2013 Oct 2;310(13):1369-76
pubmed: 24084922
Clin Biochem. 2015 Dec;48(18):1283-90
pubmed: 26118474
Pharmacol Res. 2016 Dec;114:299-300
pubmed: 27693275
Anesth Analg. 2017 Jul;125(1):362-363
pubmed: 28617700
Anesthesiology. 2004 Apr;100(4):806-10; discussion 5A
pubmed: 15087614
Sleep Med. 2009 Sep;10 Suppl 1:S12-6
pubmed: 19647481
Exp Physiol. 2009 Feb;94(2):228-39
pubmed: 19028810
Pediatrics. 2007 Dec;120 Suppl 4:S164-92
pubmed: 18055651
Clin Pharmacokinet. 2009;48(10):635-51
pubmed: 19743886